Skip to content
stoqly
en

Languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Skye Bioscience, Inc.

SKYE Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Download report 3-page PDF: the company, its results and charts with peers.

Last close Β· Oct 23, 2026

$1.54

4.9%

What Skye Bioscience, Inc. does

SKYE Β· Pharmaceutical Preparations

No business description yet.

Legal name
Skye Bioscience, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 10, 2026
Accession Β· CIK
0001628280-26-016394
0001516551
Charts by

KIRA’s summary AI analyst

Hi! I read Skye Bioscience, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

2 to watch

Skye Bioscience, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$55.9M

No. It lost money last year.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$61.1M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$1.28 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Skye Bioscience, Inc. lost $55.9M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$43.1M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’

Sales and profit

Is it selling more, and how much does it keep?

Results dates

In plain words: Every quarter, companies publish how much they sold and earned. These are the days Skye Bioscience, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 9, 2026

Monday Β· in 15 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Source
Earnings calendar

No past results dates on file yet.

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Skye Bioscience, Inc. lost $55.9M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income
Net income
Diluted EPS
Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

KIRA Β· Free cash flow was βˆ’$43.1M in fiscal 2025, β€” of revenue.

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Insider trades

KIRA Β· No open-market insider trades in the last 12 months.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

β€”

$0.0M

No open-market insider trades in the last 12 months.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Skye Bioscience, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $9.0M$1.2M$1.3M$68.4M$25.7M
Interest coverage βˆ’10.2xβˆ’27.5xβˆ’38.3xβˆ’40.3xβ€”
Current ratio 2.5x0.7x0.8x16.3x3.3x
Quick ratio 2.5x0.7x0.8x16.3x3.3x
Total assets $9.9M$9.1M$11.9M$72.8M$28.3M
Total liabilities $4.0M$12.1M$14.1M$4.6M$8.3M
Shareholders' equity $5.9Mβˆ’$3.0Mβˆ’$2.1M$68.2M$20.0M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ“ βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ“ βœ• βœ“ βœ• βœ“ βœ• βœ• βœ“ βœ•
Cash from operations exceeds net income βœ• βœ• βœ“ βœ• βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” βœ“ βœ• βœ“ βœ“ βœ• βœ• βœ“ βœ“ βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ“ βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€” β€” β€” β€” β€” β€” β€”
F-score β€” / 3β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6
Accruals ratio 115.9%53.8%βˆ’1,213.2%358.1%βˆ’21.7%βˆ’32.7%βˆ’71.0%βˆ’225.1%βˆ’3.1%βˆ’25.5%
Altman Z'' βˆ’212.62βˆ’134.34βˆ’119.27βˆ’71.09βˆ’58.26βˆ’15.65βˆ’39.93βˆ’49.4412.85βˆ’28.41

All figures

Every number, year by year.

10 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Research and development $0.9M $0.3M $0.3M $2.2M $1.9M $2.9M $6.0M $5.8M $18.7M $42.4M
Operating income βˆ’$4.5M βˆ’$3.9M βˆ’$4.7M βˆ’$6.6M βˆ’$6.3M βˆ’$7.8M βˆ’$18.3M βˆ’$34.7M βˆ’$30.2M βˆ’$58.2M
Interest expense β€” $0.0M $0.1M $1.0M $0.7M $0.8M $0.7M $0.9M $0.7M $0.0M
Pretax income βˆ’$3.2M βˆ’$3.1M βˆ’$19.2M $1.1M βˆ’$6.6M βˆ’$8.5M βˆ’$19.5M βˆ’$37.6M βˆ’$26.6M βˆ’$55.9M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Net income βˆ’$3.2M βˆ’$3.1M βˆ’$19.2M $1.1M βˆ’$6.6M βˆ’$8.5M βˆ’$19.5M βˆ’$37.6M βˆ’$26.6M βˆ’$55.9M
Net income to common βˆ’$3.5M βˆ’$4.1M βˆ’$19.2M $1.1M βˆ’$6.6M βˆ’$8.5M βˆ’$19.5M βˆ’$37.6M βˆ’$26.6M βˆ’$55.9M
Diluted EPS βˆ’$0.17 βˆ’$0.11 βˆ’$0.16 βˆ’$0.05 βˆ’$0.03 βˆ’$0.02 βˆ’$8.77 βˆ’$5.37 βˆ’$0.73 βˆ’$1.41
Diluted shares 0.02B 0.03B 0.12B 0.17B 0.23B 0.41B 0.00B 0.01B 0.04B 0.04B
Cash flow
Cash from operations βˆ’$3.6M βˆ’$3.3M βˆ’$3.9M βˆ’$6.0M βˆ’$6.1M βˆ’$6.5M βˆ’$12.7M βˆ’$14.0M βˆ’$25.2M βˆ’$43.1M
Capital expenditure $0.0M $0.0M $0.0M β€” $0.0M $0.1M $0.0M $0.0M $1.6M $0.0M
Free cash flow βˆ’$3.6M βˆ’$3.4M βˆ’$3.9M β€” βˆ’$6.1M βˆ’$6.6M βˆ’$12.8M βˆ’$14.0M βˆ’$26.8M βˆ’$43.1M
Depreciation and amortization $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.1M $0.1M $0.3M $0.7M
Stock-based compensation $0.7M $0.6M $0.7M $0.7M $0.3M $0.9M $0.6M $1.0M $8.3M $7.8M
Balance sheet
Cash and short-term investments $0.1M $0.3M $1.9M $1.8M $2.5M $9.0M $1.2M $1.3M $68.4M $25.7M
Current assets $0.3M $0.6M $2.0M $2.0M $2.7M $9.6M $8.9M $11.7M $70.8M $27.1M
Current liabilities $0.7M $0.8M $15.9M $1.0M $0.8M $3.9M $12.1M $13.9M $4.3M $8.2M
Property and equipment, net $0.0M $0.0M $0.0M $0.0M $0.0M $0.1M $0.1M $0.0M $1.4M $0.9M
Total assets $0.3M $0.6M $2.0M $2.0M $2.7M $9.9M $9.1M $11.9M $72.8M $28.3M
Total liabilities $1.8M $1.4M $17.5M $1.4M $2.2M $4.0M $12.1M $14.1M $4.6M $8.3M
Preferred stock β€” β€” $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity βˆ’$2.9M βˆ’$3.6M βˆ’$15.6M $0.5M $0.5M $5.9M βˆ’$3.0M βˆ’$2.1M $68.2M $20.0M
Returns
Return on capital employed 1,320.3% 1,551.1% 33.6% βˆ’646.5% βˆ’333.7% βˆ’132.1% 608.8% 1,771.7% βˆ’44.1% βˆ’289.3%
Return on equity β€” β€” β€” β€” βˆ’1,313.6% βˆ’269.9% βˆ’1,364.2% β€” βˆ’80.5% βˆ’126.8%
Return on assets βˆ’982.7% βˆ’702.8% βˆ’1,526.8% 53.2% βˆ’281.1% βˆ’136.1% βˆ’205.4% βˆ’357.6% βˆ’62.7% βˆ’110.7%
Return on tangible equity β€” β€” β€” 191.9% βˆ’1,455.3% βˆ’145.3% β€” β€” βˆ’39.0% βˆ’279.3%
Growth
Net income growth β€” β€” β€” β€” βˆ’723.8% β€” β€” β€” β€” β€”
Share count change β€” 47.3% 334.1% 40.0% 36.5% 75.7% βˆ’99.5% 215.4% 420.8% 8.7%
Financial health
Interest coverage β€” βˆ’5,513.1x βˆ’49.5x βˆ’6.6x βˆ’8.9x βˆ’10.2x βˆ’27.5x βˆ’38.3x βˆ’40.3x β€”
Current ratio 0.4x 0.7x 0.1x 2.1x 3.4x 2.5x 0.7x 0.8x 16.3x 3.3x
Quick ratio 0.4x 0.7x 0.1x 2.1x 3.4x 2.5x 0.7x 0.8x 16.3x 3.3x
Quality scores
Altman Z'' βˆ’212.6 βˆ’134.3 βˆ’119.3 βˆ’71.1 βˆ’58.3 βˆ’15.6 βˆ’39.9 βˆ’49.4 12.9 βˆ’28.4
Accruals ratio 115.9% 53.8% βˆ’1,213.2% 358.1% βˆ’21.7% βˆ’32.7% βˆ’71.0% βˆ’225.1% βˆ’3.1% βˆ’25.5%

Source: SEC EDGAR XBRL filings (CIK 0001516551). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open